Ferriprox

RSS

deferiprone

Authorised
This medicine is authorised for use in the European Union.

Overview

Ferriprox is an ‘iron chelator’ (a substance that attaches to iron) that is used to treat iron overload (an excess of iron in the body) in patients with thalassaemia major. This is an inherited disease in which patients are unable to make enough haemoglobin, the protein found in red blood cells that carries oxygen around the body. 

Ferriprox is used:

  • on its own, when standard iron chelator treatment cannot be used or does not work well enough;
  • in combination with another iron chelator, when treatment with one iron chelator on its own does not work or when iron levels need to be rapidly or intensively corrected to prevent or treat life-threatening conditions (mainly affecting the heart). 

Ferriprox contains the active substance deferiprone.

This EPAR was last updated on 20/05/2020

Authorisation details

Product details
Name
Ferriprox
Agency product number
EMEA/H/C/000236
Active substance
Deferiprone
International non-proprietary name (INN) or common name
deferiprone
Therapeutic area (MeSH)
  • beta-Thalassemia
  • Iron Overload
Anatomical therapeutic chemical (ATC) code
V03AC02
Publication details
Marketing-authorisation holder
Chiesi Farmaceutici S.p.A.
Revision
27
Date of issue of marketing authorisation valid throughout the European Union
25/08/1999
Contact address

Via Palermo 26/A
43122 Parma
Italy

Product information

04/05/2020 Ferriprox - EMEA/H/C/000236 - T/0146

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

All other therapeutic products

Therapeutic indication

Ferriprox monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.

Ferriprox in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload (mainly cardiac overload) justifies rapid or intensive correction.

Assessment history

How useful was this page?

Add your rating
Average
1 rating